Bobcat Bio
PrivateLast Round
Series A
Extension
Feb 25, 2025
Est. Valuation
$49.8M
Total Funding Raised
$87.49M
Company Overview
Bobcat Bio is a biotechnology company that develops autologous macrophage cell therapies for the treatment of solid tumors and hematological malignancies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Bobcat Bio Comparables
Compare Bobcat Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Avstera Therapeutics | 83% | |
| Inceptor Bio | 82% | |
| Carisma Therapeutics | 81% |
Bobcat Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Feb 25, 2025 | ||||
| Grant | Aug 8, 2024 | ||||
| Series B | Jan 22, 2024 | ||||
| Grant | Sep 1, 2023 | ||||
| Series A | Sep 29, 2021 | ||||
Series A | Jul 23, 2021 |
Bobcat Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| BioAdvance Capital | Series A, Series A Extension |
| Biolocity | Series B |
| Bios Partners | Series A Extension, Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 29, 2021
$27M round led by Bios Partners.
Bobcat Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Bobcat Bio's valuation, stock price, and market status.
Is SIRPant Immunotherapeutics a public or private company?
SIRPant Immunotherapeutics is a private company.
What is the current stock price of SIRPant Immunotherapeutics?
SIRPant Immunotherapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is SIRPant Immunotherapeutics worth (valuation)?
Valuation information for SIRPant Immunotherapeutics is not publicly available.
Can I buy SIRPant Immunotherapeutics stock?
SIRPant Immunotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was SIRPant Immunotherapeutics's last funding round?
SIRPant Immunotherapeutics's most recent funding round was Series B on January 22, 2024.
Who are the main investors in SIRPant Immunotherapeutics?
Key investors in SIRPant Immunotherapeutics include Bios Partners.
Will SIRPant Immunotherapeutics IPO soon?
No public IPO plans have been announced for SIRPant Immunotherapeutics.
How can I track SIRPant Immunotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SIRPant Immunotherapeutics's secondary market activity and sign up for updates.